<DOC>
	<DOCNO>NCT00915174</DOCNO>
	<brief_summary>Primary : To assess effect repeat dose Neramexane steady-state pharmacokinetics Drospirenone [ DRSP ] Ethinyl Estradiol [ EE ] Secondary : To assess safety tolerability concomitant repeat dose treatment Neramexane fixed-combinational DRSP- EE-containing oral contraceptive [ OC ] ( Yasmin® )</brief_summary>
	<brief_title>Study Evaluate Effects Neramexane Pharmacokinetics Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Healthy adult female subject child bear potential ( include subject tubal ligation ) , white origin , able read , write fully understand German language Aged 18 45 year ( inclusive ) BMI 1828 kg/m2 body weight 5090 kg ( inclusive ) The subject require To take DRSP/EE contain OC least two dose cycle To agree use reliable non hormonal birth control method Day 1 study Period 1 Final Examination ( e.g . nonhormonal IUD , double barrier method [ e.g . condom spermicide diaphragm spermicide ] , sexual abstinence ) . Women tubal ligation sterilize partner need additional birth control method Willing able provide write informed consent inform requirement restriction study History clinically relevant allergy know hypersensitivity Neramexane/Memantine/ Amantadine derivatives Hypersensitivity Quinine History clinically relevant allergy know hypersensitivity inactive ingredient use study medication ( Neramexane , Yasmin® , Placebo ) tool substance History clinically relevant allergy know hypersensitivity DRSP/EE Clinically relevant finding mammae genital examination , PAP smear ≥ III Any contraindication oral contraceptive : present past venous thromboses ( deep vein thrombosis , pulmonary embolism ) ; present past arterial thromboses ( e.g . myocardial infarction ) prodromal stage ( e.g . angina pectoris transitory ischaemic attack ) ; present past cerebrovascular insult ; presence serious risk factor several risk factor arterial thrombosis : diabetes mellitus vascular change , severe hypertension , severe lipid metabolism disturbance ; know suspect genetic acquire predisposition venous arterial thromboses like APC resistance , know suspected genetic lack antithrombin III , lack protein C , lack protein S , hyperhomocysteinaemia antiphospholipid antibody ( anticardiolipin antibody , lupus anticoagulant ) ; present past pancreatitis accompany severe hypertriglyceridaemia ; present past severe hepatic disease long liver function test normalize ; severe renal insufficiency acute renal failure ; present past hepatic tumor ( benign malign ) ; know suspect sexual hormone dependent , malign tumor ( e.g . genital organ mamma ) ; diagnostic clarify vaginal bleeding ; anamnesis migraine focal neurologic symptom ; know hereditary angioedema Exposure another investigational agent within last two month Day 1 Period 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>drug-drug interaction study</keyword>
</DOC>